← SynDRA
RADOTINIB
SynDRA canonical compound SYN0039670 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | ABL1 | BCR |
|---|
| Mechanism of action | Bcr-Abl kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- ABL1 INHIBITOR
- BCR INHIBITOR
- Bcr-Abl kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA3
- KDR
- NR1I2
- ACHE
- PDE3A
- KCNH2
- MAOA
- MC3R
- OPRM1
- PDE4A
- HTR2A
- PDE4D
- PGR
- PTGS1
- SLC6A2
- SLC6A3
- SLC6A4
- HTR2B
- HTR1A
- ADORA2A
- CHRM2
- ADRA1A
- ADRA2A
- ADRA2C
- ADRB1
- AR
- CHRM1
- CHRNA4
- HRH3
- DRD1
- DRD2
- DRD3
- ESR1
- F2
- HRH1
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- IY5511HCl
- radotinib dihydrochloride
- radotinib hydrochloride
- IY-5511
- IY5511
- supect
- IY-GV50205
- Anticancer, Il-yang
- I284LJY110
- radotinibum
- RefChem:178558
- DTXCID60161560
- Radotinib [INN]
- MFCD27956910
- UNII-I284LJY110
- RADOTINIB [MI]
- Radotinib (IY-5511)
- Radotinib; IY-5511;
- RADOTINIB [WHO-DD]
- Radotinib (IY-5511)?
- GTPL7814
- orb1305681
- SCHEMBL3359952
- SCHEMBL29366343
- SCHEMBL29381661
- C27H21F3N8O
- DUPWHXBITIZIKZ-UHFFFAOYSA-N
- GLXC-23325
- GLXC-90289
- HMS5086K07
- EX-A1035
- BDBM50590368
- EBC-17142
- NSC800989
- s8134
- AKOS026750428
- AKOS032950010
- CCG-269914
Look up RADOTINIB in the interactive SynDRA portal →